These results elucidate, the preferred and potentially more effective real-world first-line approach in HR+/HER2+ breast cancer is hormonal treatment, particularly for those patients who have diminished physiological function, grade 1/grade 2 disease, and no visceral involvement. The gene discussed is ERBB2; the disease is breast cancer.